EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
EXELIXIS, INC.
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 5, 2026
$62.68+0.45 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $16.28B
- P/E (TTM)
- 19.7
- Dividend yield
- –
EXELIXIS, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross product revenues | $3.15B | $3.09B | $3.01B | $2.95B | $2.82B | $2.68B | $2.52B | $2.41B | $2.36B | $2.31B | $2.27B | $2.20B | 129.4% | +11.9% |
| Net product revenues | $2.22B | $2.16B | $2.12B | $2.09B | $2.03B | $1.94B | $1.81B | $1.72B | $1.67B | $1.64B | $1.63B | $1.58B | 91.0% | +9.4% |
| CABOMETYX | $2.21B | $2.16B | $2.11B | $2.08B | $2.02B | $1.93B | $1.80B | $1.71B | $1.66B | $1.63B | $1.61B | $1.56B | 90.6% | +9.5% |
| License revenues | $239.35M | $228.84M | $214.38M | $197.36M | $201.36M | $347.05M | $349.24M | $345.13M | $327.26M | $185.02M | $178.64M | $171.49M | 9.8% | +18.9% |
| Collaboration revenues | $218.41M | $210.99M | $197.32M | $196.76M | $203.42M | $354.77M | $359.31M | $358.10M | $342.04M | $202.64M | $201.33M | $197.51M | 9.0% | +7.4% |
| COMETRIQ | $9.48M | $9.23M | $9.44M | $10.01M | $9.35M | $11.46M | $11.16M | $10.35M | $12.30M | $14.42M | $13.94M | $17.19M | 0.4% | +1.4% |
| Collaboration services revenues | – | – | – | -$601.00K | $2.05M | $7.72M | $10.06M | $12.97M | $14.78M | $17.63M | $22.69M | $26.03M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.24B | $2.18B | $2.14B | $2.11B | $2.04B | $1.96B | $1.82B | $1.74B | $1.68B | $1.66B | $1.65B | $1.59B | 91.8% | +9.4% |
| Europe | $170.00M | $161.03M | $154.17M | $156.00M | $162.11M | $315.64M | $318.63M | $316.03M | $300.97M | $147.14M | $144.97M | $143.29M | 7.0% | +4.9% |
| Japan | $30.59M | $32.73M | $25.59M | $24.69M | $25.36M | $25.05M | $27.08M | $29.04M | $28.33M | $39.26M | $39.49M | $37.51M | 1.3% | +20.6% |
From the segment and revenue-disaggregation notes of Exelixis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.